SCHEMBL23144207

SCHEMBL23144207

CC(C)(C)OC(=O)N(C(=O)OC(C)(C)C)c1ccc(S(C)(=O)=O)cc1C(F)(F)F

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ HRH4 Q9H3N8 1/20 0.43
▸ KIF11 P52732 1/20 0.39
▸ PDK1 Q15118 1/20 0.38
▸ PDK2 Q15119 1/20 0.38
▸ PDK3 Q15120 1/20 0.38
▸ PDK4 Q16654 1/20 0.38
▸ GPR119 Q8TDV5 5/20 0.36
▸ PTGS2 P35354 2/20 0.36
▸ PTGS1 P23219 1/20 0.36
▸ CACNA1B Q00975 2/20 0.35
▸ NR1I2 O75469 1/20 0.35
▸ LMNA P02545 1/20 0.34
▸ POLB P06746 1/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ CCR2 P41597 1/20 0.34
▸ CYP11B1 P15538 1/20 0.34
▸ CYP11B2 P19099 1/20 0.34
▸ ESR1 P03372 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29811800 1.00 HRH4 (0.43) HRH4KIF11PDK1PDK2PDK3
SCHEMBL23144238 0.82 KCNH2 (0.39) HRH4PDK1PDK2PDK3PDK4
SCHEMBL29812119 0.81 HRH4 (0.38) HRH4KIF11GPR119CACNA1BNR1I2
SCHEMBL23144395 0.81 HRH4 (0.38) HRH4KIF11GPR119CACNA1BNR1I2
SCHEMBL31363594 0.81 GPR119 (0.37) PDK1PDK2PDK3PDK4GPR119
SCHEMBL24427640 0.80 SOS1 (0.40) HRH4CACNA1BLMNAPOLBSMN1; SMN2
SCHEMBL11927854 0.80 POLB (0.41) KIF11PTGS1CACNA1BLMNAPOLB
SCHEMBL29534370 0.80 POLB (0.41) KIF11PTGS1CACNA1BLMNAPOLB
SCHEMBL11927855 0.78 ALDH1A1 (0.41) PDK1PDK2PDK3PDK4LMNA
SCHEMBL25033220 0.78 GPR119 (0.33) GPR119LMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260098032-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION PMV PHARMACEUTICALS INC (US) 2026-04-09 — — US disclosed
EP-4644387-A2 METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION PMV Pharmaceuticals, Inc. (US) 2025-11-05 — — EP disclosed
US-12428406-B2 Methods and compounds for restoring mutant p53 function PMV PHARMACEUTICALS, INC. (US) 2025-09-30 — — US disclosed
US-11814373-B2 Methods and compounds for restoring mutant p53 function PMV PHARMACEUTICALS, INC. (US) 2023-11-14 — — US disclosed
US-20230312539-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION PMV PHARMACEUTICALS, INC. 2023-10-05 — — US disclosed
US-20220315564-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION PMV PHARMACEUTICALS, INC. 2022-10-06 — — US disclosed
WO-2021061643-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION PMV PHARMACEUTICALS, INC. (US) 2021-04-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12428406-B2 Methods and compounds for restoring mutant p53 function TP53, TP53BP1, KRAS HRH4 4627/4885KIF11 3015/4885PDK1 669/4885
US-20230312539-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION TP53, TP53BP1, KRAS HRH4 4627/4885KIF11 3015/4885PDK1 669/4885
US-20220315564-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION TP53, TP53BP1, KRAS HRH4 4627/4885KIF11 3015/4885PDK1 669/4885
US-11814373-B2 Methods and compounds for restoring mutant p53 function TP53, TP53BP1, KRAS HRH4 4627/4885KIF11 3015/4885PDK1 669/4885
US-20260098032-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION TP53, TP53BP1, MDM2 HRH4 4814/4885KIF11 2012/4885PDK1 2557/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback